🧪
hypothesis

Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance

Hypothesis

Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance

Timed OX1R/OX2R antagonism during the rest phase may consolidate sleep, improve glymphatic/interstitial clearance, and reduce amyloid or tau stress while avoiding daytime cognitive suppression.
🧬 HCRTR2🩺 neurodegeneration🎯 Composite 76%💱 $0.58▼26.7%proposed
EvidenceStrong (64%)📖 8 cit🗣 1 debates 8 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.77 (15%) Evidence 0.73 (15%) Novelty 0.58 (12%) Feasibility 0.84 (12%) Impact 0.76 (12%) Druggability 0.86 (10%) Safety 0.70 (8%) Competition 0.55 (6%) Data Avail. 0.65 (5%) Reproducible 0.62 (5%) KG Connect 0.58 (8%) 0.758 composite
🏆 ChallengeSolve: Night-phase orexin receptor antagonism rescues AD by restoring sleep-depe$126K →
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite76%

🧪 Overview

Timed OX1R/OX2R antagonism during the rest phase may consolidate sleep, improve glymphatic/interstitial clearance, and reduce amyloid or tau stress while avoiding daytime cognitive suppression. The therapeutic effect should depend on circadian timing.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
A["Night-phase OX1R/OX2R Antagonism"] -->|"Restores sleep architecture"| B["Sleep Consolidation"]
A -->|"Target: HCRTR2"| C["Orexin Signaling Suppression"]
C -->|"Disinhibition of NREM sleep"| B
B -->|"Enhances convective flow"| D["Glymphatic Clearance Activation"]
D -->|"Increases ISF drainage"| E["Interstitial A-beta Reduction"]
D -->|"Clears metabolite waste"| F["Tau Phosphorylation Decrease"]
E -->|"Reduces seeding events"| F
F -->|"Prevents neurofibrillary tangle formation"| G["Synaptic Protection"]
A -->|"Avoids daytime orexin blockade"| H["Preserved Daytime Cognition"]
G -->|"Maintains neuronal signaling"| I["Cognitive Function Rescue"]
H -->|"No executive suppression"| I
E -->|"Decreases amyloid plaque burden"| I
G -->|"Prevents progressive neurodegeneration"| J["AD Pathology Attenuation"]
I -->|"Clinical benefit"| K["Memory Improvement"]
K -->|"Therapeutic outcome"| L["Disease Modification"]

⚖️ Evidence

⚖️ Evidence Matrix6 supports1 contradicts
Supports
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Front Neurol Neurosci2021PMID:34052813
Supports
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer's Disease.
Int J Biol Sci2021PMID:34239348medium
Supports
Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation.
ACS Chem Neurosci2022PMID:36350059medium
Supports
Quantitative Assessment of Hippocampal Tau Pathology in AD and PART.
J Mol Neurosci2020PMID:32372343medium
Supports
Roles of Microglia in AD Pathology.
Curr Alzheimer Res2023PMID:36740796medium
Supports
TDP-43 pathology is associated with increased tau burdens and seeding.
Mol Neurodegener2023PMID:37777806medium
Contradicts
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic stability during propofol, dexmedetomidine, and remifentanil anesthesia.
Pharmacol Rep2025PMID:40439868
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — HCRTR2

No curated PDB or AlphaFold mapping for HCRTR2 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for HCRTR2 from GTEx v10.

Hypothalamus0.8 Frontal Cortex BA90.4 Cortex0.3 Anterior cingulate cortex BA240.3 Nucleus accumbens basal ganglia0.2 Substantia nigra0.2 Amygdala0.2 Caudate basal ganglia0.1 Putamen basal ganglia0.1 Cerebellum0.0 Cerebellar Hemisphere0.0 Hippocampus0.0 Spinal cord cervical c-10.0median TPM (GTEx v10)

💉 Clinical Trials (3)Relevance: 76%

0
Active
0
Completed
0
Total Enrolled
PHASE2
Highest Phase
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer DiseasePHASE4
RECRUITING·NCT05924425 · University Hospital, Montpellier
Alzheimer Disease Insomnia Disorder Sleep
Daridorexant 50 mg Placebo Polysomnography
Daridorexant for Alzheimer Disease PreventionPHASE2
RECRUITING·NCT07213349 · Douglas Mental Health University Institute
Alzheimer Disease (AD)
Daridorexant 50 mg Placebo
DORA and LP in Alzheimer's Disease BiomarkersPHASE2
RECRUITING·NCT06274528 · Washington University School of Medicine
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HCRTR2 →

No DepMap CRISPR Chronos data found for HCRTR2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.8%
Volatility
Low
0.0099
Events (7d)
3
Price History
▼26.7%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

View on SciDEX ↗